Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 586 AL 600

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression

Di Domenico F, Owen JB, Sultana R, Sowell RA, Perluigi M, Cini C, Cai J, Pierce WM, Butterfield DA.

J Neurosci Res. 2010 Dec;88(16):3566-77. doi: 10.1002/jnr.22528. Epub 2010 Oct 8.

Beclin 1 complex in autophagy and Alzheimer disease

Jaeger PA, Wyss-Coray T.

Arch Neurol. 2010 Oct;67(10):1181-4. doi: 10.1001/archneurol.2010.258.

Reduced precuneus deactivation during object naming in patients with mild cognitive impairment, Alzheimer's disease, and frontotemporal lobar degeneration

Frings L, Dressel K, Abel S, Saur D, Kümmerer D, Mader I, Weiller C, Hüll M.

Dement Geriatr Cogn Disord. 2010;30(4):334-43. doi: 10.1159/000320991. Epub 2010 Oct 11.

Investigational medications for treatment of patients with Alzheimer disease

Potter PE.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.

Recruitment of subjects into clinical trials for Alzheimer disease

Knebl JA, Patki D.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.

Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?

Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.

Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.

Novel drug targets based on metallobiology of Alzheimer's disease

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.

Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.

Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease

da Cruz e Silva OA, Henriques AG, Domingues SC, da Cruz e Silva EF.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):720-6. doi: 10.2174/187152710793237458.

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease]

Wang XH, Yang W, Qi JS.

Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.

Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish brain power initiative

Oksengard AR, Cavallin L, Axelsson R, Andersson C, Nägga K, Winblad B, Eriksdotter-Jönhagen M, Wahlund LO.

Dement Geriatr Cogn Disord. 2010;30(4):374-80. doi: 10.1159/000321121. Epub 2010 Oct 16.

N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers

Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, Epstein AL, De Felice FG, Jerusalinsky D, Ferreira ST.

J Neurochem. 2010 Dec;115(6):1520-9. doi: 10.1111/j.1471-4159.2010.07058.x. Epub 2010 Nov 11.

MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains

Satoh J.

J Pharmacol Sci. 2010;114(3):269-75. doi: 10.1254/jphs.10r11fm. Epub 2010 Oct 9.

[Molecular targeted therapy in Alzheimer disease]

Morohashi Y, Tomita T, Iwatsubo T.

Nihon Rinsho. 2010 Oct;68(10):1906-10.

The genetics of Alzheimer disease: back to the future

Bertram L, Lill CM, Tanzi RE.

Neuron. 2010 Oct 21;68(2):270-81. doi: 10.1016/j.neuron.2010.10.013.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias